Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;12(1):e220106.
doi: 10.2217/cer-2022-0106. Epub 2022 Dec 14.

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Nick Ballew  1 , Aneela Mian  2 , Roger Abramino Levy  3 , Matt Bradley  4
Affiliations
Comment

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Nick Ballew et al. J Comp Eff Res. 2023 Jan.
No abstract available

Keywords: clinical trials; comparative effectiveness research; evidence-based medicine; health technology assessment; immunology; pharmaceuticals; randomized controlled trials; rheumatology.

PubMed Disclaimer

Conflict of interest statement

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Comment in

Comment on

References

    1. Bruce IN, Golam S, Steenkamp J et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J. Comp. Eff. Res. 11(10), 765–777 (2022). - PubMed
    1. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Making 33(5), 607–617 (2013). - PMC - PubMed
    1. Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200–211 (2018). - PMC - PubMed
    1. Morand EF, Furie R, Tanaka Y et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382(3), 211–221 (2020). - PubMed
    1. Furie RA, Morand EF, Bruce IN et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase III trial. Lancet Rheumatol. 1(4), e208–e219 (2019). - PubMed